Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.56 |
| ▸ | CA1 | P00915 | 11/20 | 0.56 |
| ▸ | CA9 | Q16790 | 11/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA6 | P23280 | 4/20 | 0.56 |
| ▸ | CA5A | P35218 | 4/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA4 | P22748 | 3/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202947 | 0.81 | CA2 (0.70) | CA2CA1CA9CA12CA6 | |
| SCHEMBL10749655 | 0.78 | CA2 (0.67) | CA2CA1CA9CA12CA6 | |
| SCHEMBL10750170 | 0.78 | CA2 (0.67) | CA2CA1CA9CA12CA6 | |
| SCHEMBL10750176 | 0.78 | CA2 (0.67) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1806991 | 0.75 | CA2 (0.56) | CA2CA1CA9CA12CA6 | |
| SCHEMBL95810 | 0.75 | BCAT2 (0.40) | CA2CA1CA9CA12CA6 | |
| SCHEMBL332245 | 0.75 | TSHR (0.44) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1080972 | 0.74 | CA2 (0.61) | CA2CA1CA9CA12CA6 | |
| SCHEMBL344271 | 0.72 | CA2 (1.00) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1808913 | 0.72 | CA2 (0.58) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | claimed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | claimed |
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | MERCK PATENT GMBH (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2462141-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | Merck Patent GmbH (DE) | 2012-06-13 | — | — | EP | claimed |
| WO-2011017009-A1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2011-02-10 | — | — | WO | claimed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-0257787-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE BENZENE-SULFONAMIDE DERIVATES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-04-17 | — | — | EP | claimed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-2968237-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968257-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2919788-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2015-09-23 | — | — | EP | disclosed |
| US-4931581-A | CHEMICAL INTERMEDIATES FOR 1,2,3-BENZOTHIADIAZOLE DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1990-06-05 | — | — | US | disclosed |
| US-4766120-A | ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1988-08-23 | — | — | US | disclosed |
| US-4663323-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| EP-0035046-B1 | NOVEL TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4540703-A | Tetrazole derivatives, anti-ulcer composition containing the same and method for treating ulcers | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1985-09-10 | — | — | US | disclosed |
| EP-0035046-A1 | Novel tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277228-A1 | Novel Azaheterocyclic Compounds | PCNA, MCL1, MYC | CA2 4731/4885CA1 4838/4885CA9 3755/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CA2 1456/4885CA1 631/4885CA9 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.